[Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution (Patanol 0.1% ophthalmic solution)].
Watanabe
Masakazu
M
Masakazu.Watanabe@AlconLabs.com
Kodama
Hiroshi
H
Hasegawa
Koji
K
Itoh
Kaiko
K
D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D002986:Clinical Trials as Topic; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D016207:Cytokines / Q000378:metabolism; D003990:Dibenzoxepins / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D006633:Histamine Antagonists; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy; D018836:Inflammation Mediators / Q000378:metabolism; D000069605:Olopatadine Hydrochloride; D009883:Ophthalmic Solutions; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016207:Cytokines; D003990:Dibenzoxepins; D006633:Histamine Antagonists; D018836:Inflammation Mediators; D009883:Ophthalmic Solutions; D014409:Tumor Necrosis Factor-alpha; D000069605:Olopatadine Hydrochloride